Page last updated: 2024-12-06

procymidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Procymidone is a fungicide used to control a wide range of diseases in various crops. Its synthesis involves a multi-step process starting with the reaction of 2,6-dichlorobenzoyl chloride with 3-amino-4-chloro-1,2,5-thiadiazole. Procymidone acts by inhibiting the biosynthesis of sterols in fungi, which are essential components of their cell membranes. This disrupts the normal growth and development of the fungus, leading to its control. The importance of procymidone lies in its broad-spectrum fungicidal activity, its effectiveness in controlling economically important diseases, and its low mammalian toxicity. It is studied to understand its mode of action, its efficacy against different fungal species, and its environmental impact. Research focuses on optimizing its application, reducing its potential resistance development, and exploring its potential use in other fields, such as plant growth regulation.'

procymidone : An azabicycloalkane that is 1,5-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione in which the amino hydrogen is replaced by a 3,5-dichlorophenyl group. A fungicide widely used in horticulture as a seed dressing, pre-harvest spray or post-harvest dip for the control of various diseases. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID36242
CHEMBL ID513678
SCHEMBL ID23093
MeSH IDM0109912

Synonyms (39)

Synonym
3-(3,5-dichlorophenyl)-1,5-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione
3-azabicyclo[3.1.0]hexane-2,4-dione, 3-(3,5-dichlorophenyl)-1,5-dimethyl-
sumilex
CBDIVE_013932
NCGC00091017-01
32809-16-8
procymidone
NCGC00091017-02
AC-11632
MLS002222345
smr000765832
AKOS000545989
qxjkbpavahbarf-uhfffaoysa-
inchi=1/c13h11cl2no2/c1-12-6-13(12,2)11(18)16(10(12)17)9-4-7(14)3-8(15)5-9/h3-5h,6h2,1-2h3
CHEMBL513678
NCGC00091017-03
NCGC00091017-04
HMS3073A16
cas-32809-16-8
dtxsid9033923 ,
dtxcid7013923
tox21_303640
NCGC00257305-01
NCGC00259462-01
tox21_201913
FT-0639055
AB00078702-01
SCHEMBL23093
procymidone, pestanal(r), analytical standard
procymidone 100 microg/ml in isooctane
procymidone 10 microg/ml in cyclohexane
J-018891
procymidone, certified reference material, tracecert(r)
5-methoxy-2-(trifluoromethyl)-benzoic acid
Q416120
procymidone 1000 microg/ml in acetone
(1s)-3-(3,5-dichlorophenyl)-1,5-dimethyl-3-azabicyclo[3.1.0]hexane-2,4-dione
AS-75497
CS-0013948

Research Excerpts

Overview

Procymidone (PCM) is a fungicide commonly used to prevent and control plant diseases. It is also an environmental endocrine disruptor that has a typical anti-androgen effect on the function and/or structure of the vertebrate reproductive system.

ExcerptReferenceRelevance
"Procymidone (PCM) is a fungicide commonly used to prevent and control plant diseases, and it is also an environmental endocrine disruptor that has a typical anti-androgen effect on the function and/or structure of the vertebrate reproductive system. "( Combined effect of unfolded protein response and circZc3h4, circRNA Scar in mouse ovary and uterus damage induced by procymidone.
Fu, H; Li, R; Wang, Q; Wang, Z; Xin, B; Yan, Z; Zhu, Y, 2022
)
2.37
"Procymidone is a dicarboximide fungicide mainly used for vineyard protection but also for different crops. "( Ultraviolet degradation of procymidone--structural characterization by gas chromatography coupled with mass spectrometry and potential toxicity of photoproducts using in silico tests.
Bouchonnet, S; Bourcier, S; Clavaguera, C; Genty, C; Jaber, F; Rifai, A; Souissi, Y, 2013
)
2.13
"Procymidone is a fungicide with anti-androgenic properties, widely used to protect fruits from fungal infection. "( Influence of long-term dietary administration of procymidone, a fungicide with anti-androgenic effects, or the phytoestrogen genistein to rats on the pituitary-gonadal axis and Leydig cell steroidogenesis.
Seidlova-Wuttke, D; Söder, O; Strand, ML; Supornsilchai, V; Svechnikov, K; Wahlgren, A; Wuttke, W, 2005
)
2.03
"Procymidone is a dicarboximide fungicide structurally related to the well-characterized fungicide vinclozolin. "( The fungicide procymidone alters sexual differentiation in the male rat by acting as an androgen-receptor antagonist in vivo and in vitro.
Gray, LE; Kelce, WR; Lambright, C; Mann, P; Ostby, J; Wolf, CJ,
)
1.93

Actions

ExcerptReferenceRelevance
"Procymidone can cause damage to the structure and function of testes, reduce sperm quality, and increase the expression of certain pro-apoptotic genes in adolescent male mice."( [Injury of procymidone on testis and sperm in the male adolescent mice].
Fu, H; Li, R; Wang, Z; Yan, Z; Zhu, Y, 2020
)
2.39

Toxicity

ExcerptReferenceRelevance
" Adverse effects were observed in young and adult male offspring from the group exposed to the highest dose of the mixture."( Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides.
Axelstad, M; Berthelsen, LO; Boberg, J; Christiansen, S; Hass, U; Isling, LK; Jacobsen, PR; Mandrup, KR; Vinggaard, AM, 2012
)
0.38
" Among them, 3,5-dichloroaniline presents a predicted rat LD50 toxicity about ten times greater than that of procymidone."( Ultraviolet degradation of procymidone--structural characterization by gas chromatography coupled with mass spectrometry and potential toxicity of photoproducts using in silico tests.
Bouchonnet, S; Bourcier, S; Clavaguera, C; Genty, C; Jaber, F; Rifai, A; Souissi, Y, 2013
)
0.9
" These results demonstrated that exposure to CBZ + PRO caused more serious lipid metabolism disorder in the liver than exposure to a single fungicide, which could provide some new insight for the toxic effects after fungicides joint exposure."( Insights into enhanced toxic effects by the binary mixture of carbendazim and procymidone on hepatic lipid metabolism in mice.
Bao, Z; Jin, Y; Luo, T; Wang, D; Yang, G; Zhao, Y, 2023
)
1.14

Dosage Studied

The aim of this study was to assess whether the joint effects of three androgen receptor antagonists (vinclozolin, flutamide, procymidone) on male sexual differentiation after in utero and postnatal exposures can be predicted based on dose-response data.

ExcerptRelevanceReference
" The current study was designed to determine if procymidone acted as an AR antagonist in vitro and to describe the dosage levels of procymidone that alter sexual differentiation in vivo."( The fungicide procymidone alters sexual differentiation in the male rat by acting as an androgen-receptor antagonist in vivo and in vitro.
Gray, LE; Kelce, WR; Lambright, C; Mann, P; Ostby, J; Wolf, CJ,
)
0.75
" Male offsprings display a higher incidence of epididymal and testicular lesions than generally seen with flutamide, P, or V even at high dosage levels."( Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differen
Cooper, RL; Gray, LE; Lambright, C; Mann, P; Ostby, J; Price, M; Wolf, C,
)
0.38
" Dosing the animals with a combination of a 1:1 mixture of vinclozolin and procymidone resulted in a weight reduction in the reproductive organs and an increase of serum LH and FSH as early as with 10 mg/kg combined dose."( The combined effects of vinclozolin and procymidone do not deviate from expected additivity in vitro and in vivo.
Dalgaard, M; Lam, HR; Nellemann, C; Vinggaard, AM, 2003
)
0.82
" Castration of sexually immature Sprague-Dawley rats was performed between post-natal days 42 and 46 whilst dosing of the chemical over 10 days was performed between post-natal days 53 and 67."( Evaluation of the rodent Hershberger assay using three reference endocrine disrupters (androgen and antiandrogens).
Bars, RG; Kennel, PF; Pallen, CT,
)
0.13
" A subset of testosterone treated animals was then dosed with 200 mg/kg of either fungicide in corn oil."( Gene expression analysis in the ventral prostate of rats exposed to vinclozolin or procymidone.
Gray, LE; Rosen, MB; Schmid, JE; Wilson, VS,
)
0.36
" The aim was to assess whether the joint effects of vinclozolin, flutamide, and procymidone can be predicted based on dose-response data of the individual chemicals."( Dysgenesis and histological changes of genitals and perturbations of gene expression in male rats after in utero exposure to antiandrogen mixtures.
Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kiersgaard, MK; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007
)
0.57
"The aim of this study was to assess whether the joint effects of three androgen receptor antagonists (vinclozolin, flutamide, procymidone) on male sexual differentiation after in utero and postnatal exposures can be predicted based on dose-response data of the individual chemicals."( Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat.
Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007
)
0.55
" Changes in anogenital distance (AGD) and nipple retention (NR) in male offspring rats were chosen as end points for extensive dose-response studies."( Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat.
Axelstad, M; Christiansen, S; Dalgaard, M; Hass, U; Kortenkamp, A; Metzdorff, SB; Scholze, M; Vinggaard, AM, 2007
)
0.34
" Rats were dosed during pregnancy with antiandrogens singly or in pairs at dosage levels equivalent to about one half of the ED50 for hypospadias or epididymal agenesis."( Cumulative effects of in utero administration of mixtures of "antiandrogens" on male rat reproductive development.
Furr, JR; Gray, LE; Hotchkiss, AK; Howdeshell, KL; Lambright, CR; Rider, CV; Wilson, VS, 2009
)
0.35
" In both rats dosed with PCM-CH2OH and PA-CH2OH, the radioactivity was similarly distributed into plasma and tissues, and PA-CH2OH was detected as the main metabolite in plasma, whereas PCM-CH2OH predominated in tissues except for kidney at 1 h after administration of PA-CH2OH."( Metabolism of procymidone derivatives in female rats.
Abe, J; Kaneko, H; Kawamura, S; Tarui, H; Tomigahara, Y, 2009
)
0.71
" This as well as the predictability of the combination effects based on dose-additivity modelling will be studied further in a large dose-response study."( Combined exposure to endocrine disrupting pesticides impairs parturition, causes pup mortality and affects sexual differentiation in rats.
Boberg, J; Christiansen, S; Hass, U; Jacobsen, PR; Nellemann, C, 2010
)
0.36
" In all binary mixture studies, rats were dosed during pregnancy with chemicals, singly or in pairs, at dosage levels equivalent to approximately one-half of the ED50 for hypospadias or epididymal agenesis."( Cumulative effects of in utero administration of mixtures of reproductive toxicants that disrupt common target tissues via diverse mechanisms of toxicity.
Furr, JR; Gray, LE; Rider, CV; Wilson, VS, 2010
)
0.36
" Pregnant and lactating rat dams were dosed with a mixture of the five pesticides at three different doses, or with the individual pesticides at one of two doses."( Persistent developmental toxicity in rat offspring after low dose exposure to a mixture of endocrine disrupting pesticides.
Axelstad, M; Berthelsen, LO; Boberg, J; Christiansen, S; Hass, U; Isling, LK; Jacobsen, PR; Mandrup, KR; Vinggaard, AM, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency38.57080.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency14.75650.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.85350.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency41.36820.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency47.99590.001530.607315,848.9004AID1224841; AID1224842; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency36.43390.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.27410.000229.305416,493.5996AID743069; AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.02450.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency61.40350.001019.414170.9645AID743094; AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency27.19500.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.23760.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency64.48950.001628.015177.1139AID1259395
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.79430.010039.53711,122.0200AID588545
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency141.25403.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency76.64590.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency28.72810.000627.21521,122.0200AID651741; AID743202
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency3.54810.15855.287912.5893AID540303
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency89.12516.309660.2008112.2020AID720709
Cellular tumor antigen p53Homo sapiens (human)Potency47.27860.002319.595674.0614AID651631; AID651743
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (143)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID1102032Fungistatic activity against Rhizoctonia solani assessed as mycelial growth inhibition at 200 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1102031Fungistatic activity against Rhizoctonia solani assessed as mycelial growth inhibition at 20 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1102030Fungistatic activity against Fusarium culmorum assessed as mycelial growth inhibition at 200 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112249Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as dieback lesion length at 55 g AI /100 L applied 24 hr prior inoculation to pruning wound measured after 3 months2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112229Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as non-lesion areas compound applied 24 hr prior inoculation to pruning wound measured after 1 year2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112231Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as pathogen incidence at dieback sites compound applied 24 hr prior inoculation to pruning wound measured after 1 year2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112263Fungicidal activity against Diplodia mutila Q assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1111764Fungicidal activity against Botryotinia fuckeliana assessed as inhibition of spore germination measured after 24 hr2011Pest management science, Aug, Volume: 67, Issue:8
Synthesis of 2-amino-6-oxocyclohexenylsulfonamides and their activity against Botrytis cinerea.
AID1112255Fungicidal activity against Diplodia mutila F (12)2 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112230Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as pathogen incidence at dieback edges compound applied 24 hr prior inoculation to pruning wound measured after 1 year2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1090165Fungicidal activity against Botryotinia fuckeliana assessed as mycelial growth inhibition in potato dextrose agar at 24 +/- 0.5 degC2005Journal of agricultural and food chemistry, Mar-23, Volume: 53, Issue:6
Synthesis and fungicidal activity of novel 2-oxocycloalkylsulfonylureas.
AID1112258Fungicidal activity against Neofusicoccum luteum M (13)8 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102037Fungistatic activity against Alternaria alternata assessed as mycelial growth inhibition at 200 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112260Fungicidal activity against Neofusicoccum australe J-3 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1081756Fungicidal activity against Botryotinia fuckeliana grown on compound pre-treated cucumber leaves assessed as control efficiency against gray mold disease on leaves at 31.25 ug/mL2010Journal of agricultural and food chemistry, Nov-10, Volume: 58, Issue:21
Synthesis, fungicidal activity, and structure-activity relationship of 2-oxo- and 2-hydroxycycloalkylsulfonamides.
AID1112257Fungicidal activity against Neofusicoccum luteum N(12)2 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID382908Antifungal activity against Botrytis cinerea Pers2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis and biological activities of 2-oxocycloalkylsulfonamides.
AID1081759Fungicidal activity against Botryotinia fuckeliana assessed as inhibition spore germination2010Journal of agricultural and food chemistry, Nov-10, Volume: 58, Issue:21
Synthesis, fungicidal activity, and structure-activity relationship of 2-oxo- and 2-hydroxycycloalkylsulfonamides.
AID1112238Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as pathogen incidence at 55 g AI /100 L applied 24 hr prior inoculation to pruning wound measured after 3 months2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1111762Fungicidal activity against Botryotinia fuckeliana in 2 hr compound pretreated cucumber seedling assessed as inhibition of spot diameter squared as control efficiency at 200 ug/ml measured after 72 hr2011Pest management science, Aug, Volume: 67, Issue:8
Synthesis of 2-amino-6-oxocyclohexenylsulfonamides and their activity against Botrytis cinerea.
AID1081757Fungicidal activity against Botryotinia fuckeliana grown on compound pre-treated cucumber leaves assessed as control efficiency against gray mold disease on leaves at 125 ug/mL2010Journal of agricultural and food chemistry, Nov-10, Volume: 58, Issue:21
Synthesis, fungicidal activity, and structure-activity relationship of 2-oxo- and 2-hydroxycycloalkylsulfonamides.
AID1112259Fungicidal activity against Neofusicoccum luteum G(s)-1 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1081761Fungicidal activity against Botryotinia fuckeliana assessed as inhibition of mycelial growth2010Journal of agricultural and food chemistry, Nov-10, Volume: 58, Issue:21
Synthesis, fungicidal activity, and structure-activity relationship of 2-oxo- and 2-hydroxycycloalkylsulfonamides.
AID1112254Fungicidal activity against Diplodia mutila Q assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112265Fungicidal activity against Diplodia mutila F (12)2 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102027Fungistatic activity against Phytophthora cactorum assessed as mycelial growth inhibition at 20 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1081758Fungicidal activity against Botryotinia fuckeliana grown on compound pre-treated cucumber leaves assessed as control efficiency against gray mold disease on leaves at 500 ug/mL2010Journal of agricultural and food chemistry, Nov-10, Volume: 58, Issue:21
Synthesis, fungicidal activity, and structure-activity relationship of 2-oxo- and 2-hydroxycycloalkylsulfonamides.
AID1102025Fungistatic activity against Blumeria graminis infested wheat seedling assessed as inhibition of fungal infection at 500 ug/ml applied as spray after 7 to 14 days under green house conditions relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112266Fungicidal activity against Neofusicoccum luteum M (13)8 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1111765Fungicidal activity against Botryotinia fuckeliana assessed as inhibition of mycelial growth measured after 72 hr2011Pest management science, Aug, Volume: 67, Issue:8
Synthesis of 2-amino-6-oxocyclohexenylsulfonamides and their activity against Botrytis cinerea.
AID1102034Fungistatic activity against Alternaria alternata assessed as mycelial growth inhibition at 20 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1111763Fungicidal activity against Botryotinia fuckeliana assessed as germ-tube elongation inhibition at 50 ug/ml measured after 24 hr2011Pest management science, Aug, Volume: 67, Issue:8
Synthesis of 2-amino-6-oxocyclohexenylsulfonamides and their activity against Botrytis cinerea.
AID1112267Fungicidal activity against Neofusicoccum luteum N(12)2 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102029Fungistatic activity against Fusarium culmorum assessed as mycelial growth inhibition at 20 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112269Fungicidal activity against Neofusicoccum australe J-3 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102035Fungistatic activity against Botryotinia fuckeliana assessed as mycelial growth inhibition at 200 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID632675Antifungal activity against Phytophthora capsici assessed as growth inhibition at 500 ug/mL by potted plant test2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Molecular design, synthesis and bioactivity of glycosyl hydrazine and hydrazone derivatives: notable effects of the sugar moiety.
AID1112271Fungicidal activity against Neofusicoccum australe Kat-1 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112226Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as mean pathogen compound applied 24 hr prior inoculation to pruning wound measured after 1 year2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102026Fungistatic activity against Blumeria graminis infested wheat seedling assessed as inhibition of fungal infection at 1000 ug/ml applied as spray after 7 to 14 days under green house conditions relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1102033Fungistatic activity against Botryotinia fuckeliana assessed as mycelial growth inhibition at 20 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112256Fungicidal activity against Diplodia mutila Iso-2 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112261Fungicidal activity against Neofusicoccum australe Mel-2 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112262Fungicidal activity against Neofusicoccum australe Kat-1 assessed as conidial germination inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112264Fungicidal activity against Diplodia mutila Iso-2 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112228Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as pathogen incidence at closest side shoot compound applied 24 hr prior inoculation to pruning wound measured after 6 months2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112270Fungicidal activity against Neofusicoccum australe Mel-2 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1102028Fungistatic activity against Phytophthora cactorum assessed as mycelial growth inhibition at 200 ug/ml after 4 to 8 days relative to control2003Journal of agricultural and food chemistry, Jan-15, Volume: 51, Issue:2
Synthesis and fungistatic activity of new groups of 2,4-dihydroxythiobenzoyl derivatives against phytopathogenic fungi.
AID1112227Fungicidal activity against Neofusicoccum luteum infected Pinot noir grapevine assessed as pathogen incidence at area beyond node compound applied 24 hr prior inoculation to pruning wound measured after 1 year2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID1112268Fungicidal activity against Neofusicoccum luteum G(s)-1 assessed as mycelial growth inhibition after 48 hr2012Pest management science, May, Volume: 68, Issue:5
Evaluation of fungicides for the management of Botryosphaeria dieback diseases of grapevines.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (5.04)18.7374
1990's12 (10.08)18.2507
2000's45 (37.82)29.6817
2010's35 (29.41)24.3611
2020's21 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.76 (24.57)
Research Supply Index4.85 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index58.19 (26.88)
Search Engine Supply Index2.88 (0.95)

This Compound (31.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.36%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other124 (97.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]